Effectiveness and Safety of Selective Serotonin Reuptake Inhibitors in Individuals with Williams Syndrome
Journal of Child and Adolescent Psychopharmacology · 01.08.2026 · 36 (6) · 377-381
DOI: 10.1177/10445463261451798 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, online erschienen am 13.05.2026. Verfasst von Liron Snapir und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Child and Adolescent Psychiatry, Behavioral Neurogenetics Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, …. Hauptthemen laut MEDLINE: Selective Serotonin Reuptake Inhibitors, Williams Syndrome, Depressive Disorder, Anxiety Disorders. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Autour des Williams association.
Abstract (Originalsprache)
Objective
Anxiety and depressive disorders are common in individuals with Williams syndrome (WS), yet data regarding pharmacologic treatment in this population are limited. This study aimed to evaluate the effectiveness and safety of selective serotonin reuptake inhibitors (SSRIs) in individuals with WS treated for anxiety and/or depressive disorders.
Methods
We conducted a retrospective chart review of patients with a genetically confirmed diagnosis of WS treated with SSRIs between 2010 and 2025 at a clinic for individuals with WS. Fourteen children and adults (5 males and 9 females; mean age: 23.2 ± 11.9 years) met inclusion criteria, contributing 16 distinct SSRI treatment trials. Illness severity was assessed using the Clinical Global Impressions–Severity (CGI-S) scale at baseline and last follow-up and the Clinical Global Impressions–Improvement (CGI-I) scale.
Results
The CGI-S score decreased significantly from 4.62 ± 0.81 at baseline to 3.06 ± 1.12 at last follow-up ( t (15) = 3.83, p = 0.002). Nine of 16 trials (56.2%) were rated as much or very much improved (CGI-I = 1 or 2). The mean duration of SSRI treatment was 3.95 ± 3.91 years (range: 0.75–16). Adverse events were documented in two trials (12.5%), and no treatment discontinuations due to adverse events occurred.
Conclusions
SSRI treatment was effective and well tolerated in individuals with WS. Prospective controlled studies are required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Department of Child and Adolescent Psychiatry, Behavioral Neurogenetics Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.
- Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Pediatric Molecular Psychiatry Laboratory, Sheba Medical Center, Tel Hashomer, Israel.
- Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
ORCID-Profile: Liron Snapir
Förderung
- Autour des Williams association
Zitieren
APA
Snapir, L., Elazar, M., Cohen, T., Weinberger, R., Schwartz-Lifshitz, M., Taler, M., & Gothelf, D. (2026). Effectiveness and Safety of Selective Serotonin Reuptake Inhibitors in Individuals with Williams Syndrome. Journal of Child and Adolescent Psychopharmacology, 36(6), 377-381. https://doi.org/10.1177/10445463261451798
Vancouver
Snapir L, Elazar M, Cohen T, Weinberger R, Schwartz-Lifshitz M, Taler M, et al. Effectiveness and Safety of Selective Serotonin Reuptake Inhibitors in Individuals with Williams Syndrome. Journal of Child and Adolescent Psychopharmacology. 2026;36(6):377-381. doi:10.1177/10445463261451798
BibTeX
@article{Snapir2026,
author = {Snapir, Liron and Elazar, Maya and Cohen, Tal and Weinberger, Ronnie and Schwartz-Lifshitz, Maya and Taler, Michal and Gothelf, Doron},
title = {Effectiveness and Safety of Selective Serotonin Reuptake Inhibitors in Individuals with Williams Syndrome},
journal = {Journal of Child and Adolescent Psychopharmacology},
year = {2026},
volume = {36},
number = {6},
pages = {377--381},
doi = {10.1177/10445463261451798}
}
EUVIMED